

Letter Subject: Imaverol continuity - Notification on Market Authorization and Distribution Transfer

23/03/2020

Dear Valued Customer,

As announced, Elanco Animal Health completed the divestment of its equine portfolio to Audevard Laboratories in April 2018.

In order to ensure an uninterrupted supply of products to you as our valued customer, Elanco and Audevard have committed to closely work together on a transition plan and supply agreements.

We finalized the transfer of the Market Authorization to sell the Imaverol brand to Audevard. This means that Audevard will take over the distribution of these products as per 1 April 2020.

What does this mean for you – as our valued customer – starting the 1st of April?

- The product remains the same: same Market Authorization targeting horses, cattle and dogs
- Packaging with Audevard logo is already available.
- As before, you can continue to work with us regards your supply of Imaverol
- For any questions concerning technical or pharmacovigilance matters, please contact: vetline@audevard.com

Thank you for your continuing trust and business.

Should you have any further questions, please also feel free to reach out to your usual Elanco contact, or email head office on elancoUK@elanco.com.

Sincerely,

Cecile Boyer, Innovation Manager Audvard,

Simon Harris BVetMed, MRCVS, Head of Marketing, Elanco